Traders bought shares of Merck & Co., Inc. (NYSE:MRK) on weakness during trading hours on Tuesday. $139.83 million flowed into the stock on the tick-up and $86.42 million flowed out of the stock on the tick-down, for a money net flow of $53.41 million into the stock. Of all stocks tracked, Merck & Co., Inc. had the 5th highest net in-flow for the day. Merck & Co., Inc. traded down ($0.53) for the day and closed at $54.90

Several analysts have recently commented on MRK shares. Bank of America started coverage on Merck & Co., Inc. in a report on Tuesday, November 28th. They set a “buy” rating and a $64.00 target price on the stock. BMO Capital Markets set a $70.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Wednesday, October 18th. SunTrust Banks upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and increased their target price for the stock from $54.00 to $72.00 in a report on Tuesday, January 16th. Sanford C. Bernstein restated a “buy” rating and set a $64.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, November 15th. Finally, Jefferies Group cut Merck & Co., Inc. from a “hold” rating to an “underperform” rating in a report on Wednesday, November 1st. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $66.88.

The stock has a market cap of $149,570.00, a price-to-earnings ratio of 59.03, a PEG ratio of 2.46 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.04. The business had revenue of $10.43 billion for the quarter, compared to analysts’ expectations of $10.48 billion. Merck & Co., Inc. had a return on equity of 27.73% and a net margin of 6.40%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.89 earnings per share. equities analysts expect that Merck & Co., Inc. will post 4.15 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 6th. Investors of record on Thursday, March 15th will be issued a $0.48 dividend. This represents a $1.92 annualized dividend and a yield of 3.50%. The ex-dividend date is Wednesday, March 14th. Merck & Co., Inc.’s dividend payout ratio is 206.45%.

Merck & Co., Inc. declared that its board has authorized a stock repurchase plan on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

In other Merck & Co., Inc. news, insider Weir Mirian M. Graddick sold 60,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total value of $3,697,800.00. Following the transaction, the insider now owns 101,484 shares of the company’s stock, valued at $6,254,458.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Wendell P. Weeks sold 5,000 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $53.57, for a total value of $267,850.00. Following the completion of the transaction, the director now directly owns 5,100 shares in the company, valued at approximately $273,207. The disclosure for this sale can be found here. Insiders sold 82,500 shares of company stock worth $5,026,025 in the last three months. Insiders own 0.25% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Merck & Co., Inc. by 1.7% during the second quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock worth $12,442,709,000 after purchasing an additional 3,312,459 shares during the period. BlackRock Inc. raised its position in shares of Merck & Co., Inc. by 1.0% during the second quarter. BlackRock Inc. now owns 184,997,390 shares of the company’s stock worth $11,856,484,000 after purchasing an additional 1,834,500 shares during the period. Geode Capital Management LLC raised its position in shares of Merck & Co., Inc. by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 29,116,826 shares of the company’s stock worth $1,634,999,000 after purchasing an additional 957,657 shares during the period. Franklin Resources Inc. raised its position in shares of Merck & Co., Inc. by 3.1% during the second quarter. Franklin Resources Inc. now owns 27,019,572 shares of the company’s stock worth $1,731,684,000 after purchasing an additional 801,033 shares during the period. Finally, Ameriprise Financial Inc. raised its position in shares of Merck & Co., Inc. by 7.5% during the third quarter. Ameriprise Financial Inc. now owns 23,515,877 shares of the company’s stock worth $1,505,621,000 after purchasing an additional 1,631,013 shares during the period. 72.85% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/13/investors-buy-merck-co-inc-mrk-on-weakness.html.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.